Skip to main content
SpringerLink
Log in

The choice of antihypertensive drugs in patients with diabetes: Angiotensin II and beyond

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Affecting over 16 million individuals, diabetes mellitus is among the leading causes of mortality in the United States. Hypertension is a common finding among diabetic patients and increases their morbidity and mortality. Control of blood pressure in this population has been shown to improve outcomes. Recent randomized trials have proven the benefit of lower blood pressure goals in the treatment of hypertensive patients as compared with nondiabetic patients. Randomized controlled trials have also demonstrated that the selection of the antihypertensive agent used to treat hypertension in diabetic patients is as important as the reduction of blood pressure levels to the recommended levels. In this article, we first focus on the importance of the renin angiotensin system in the development of diabetic complications, and then we review the results of the recent studies that have had a major impact on the treatment of hypertension in diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Treatment of hypertension in adults with diabetes. Diabetes Care 2002, 25(suppl 1):S71–S73.The recent guidelines of the American Diabetes Association for the treatment of hypertension in diabetic patients.

  2. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053–1059.

    PubMed  CAS  Google Scholar 

  3. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:703–713.

  4. Adler AI, Stratton IM, Neil HA, et al.: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412–419.

    Article  PubMed  CAS  Google Scholar 

  5. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  6. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677–684. This is a large-scale, randomized, placebo-controlled trial using a CCB-based regimen to treat isolated systolic hypertension. This study showed that the treatment of hypertension with nitrendipine is associated with a significant reduction in mortality, especially in the diabetic subgroup.

    Article  PubMed  CAS  Google Scholar 

  7. Hovind P, Rossing P, Tarnow L, et al.: Progression of diabetic nephropathy. Kidney Int 2001, 59:702–709.

    Article  PubMed  CAS  Google Scholar 

  8. Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646–661. Reviews the recent studies on hypertension and diabetes and provides guidelines for the treatment of hypertension and proteinuria in diabetic patients.

    PubMed  CAS  Google Scholar 

  9. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure [no authors listed]. Arch Intern Med 1997, 157:2413–2446.

  10. Alderman MH, Madhavan S, Ooi WL, et al.: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991, 324:1098–1104.

    Article  PubMed  CAS  Google Scholar 

  11. Siragy HM, Carey RM: Angiotensin type 2 receptors: potential importance in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2001, 10:99–103. Reviews the recent findings on the role of AT2 receptors in the control of blood pressure and renal function as well as their effects in vascular physiology.

    Article  PubMed  CAS  Google Scholar 

  12. Burns KD: Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000, 36:449–467. This is an in-depth review of the literature on the systemic and intrarenal RAS. It explains the changes of the RAS in diabetes. It describes the actions of Ang II through the activation of its type 1 and type 2 receptors and the clinical relevance of these interactions in diabetic nephropathy.

    PubMed  CAS  Google Scholar 

  13. Siragy HM, Carey RM: Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999, 33:1237–1242.

    PubMed  CAS  Google Scholar 

  14. Barber MN, Sampey DB, Widdop RE: AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 1999, 34:1112–1116.

    PubMed  CAS  Google Scholar 

  15. Matrougui K, Loufrani L, Heymes C, et al.: Activation of AT(2) receptors by endogenous angiotensin II is involved in flow-induced dilation in rat resistance arteries. Hypertension 1999, 34:659–665.

    PubMed  CAS  Google Scholar 

  16. Tsutsumi Y, Matsubara H, Masaki H, et al.: Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999, 104:925–935.

    Article  PubMed  CAS  Google Scholar 

  17. Carey RM, Jin XH, Siragy HM: Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 2001, 14:98S-102S.

    Article  PubMed  CAS  Google Scholar 

  18. Lonn EM, Yusuf S, Jha P, et al.: Emerging role of angiotensinconverting enzyme inhibitors in cardiac and vascular protection. Circulation 1994, 90:2056–2069.

    PubMed  CAS  Google Scholar 

  19. Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719–2728. This is a large-scale, randomized, controlled trial in African Americans with hypertensive renal disease, showing that an ACEI was superior to a dihydropyridine in preserving kidney function.

    Article  PubMed  CAS  Google Scholar 

  20. Gainer JV, Morrow JD, Loveland A, et al.: Effect of bradykininreceptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998, 339:1285–1292.

    Article  PubMed  CAS  Google Scholar 

  21. Henriksen EJ, Jacob S, Kinnick TR, et al.: ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 1999, 277:R332-R336.

    PubMed  CAS  Google Scholar 

  22. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group [no authors listed]. N Engl J Med 1987, 316:1429–1435.

  23. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293–302.

  24. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153. This is a large-scale, randomized, controlled trial in diabetic and nondiabetic patients at high risk for cardiovascular disease. This study demonstrated that treatment with an ACEI was associated with a significant reduction of cardiovascular events and the mortality associated with them.

    Article  PubMed  CAS  Google Scholar 

  25. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group [no authors listed]. Lancet 1995, 345:669–685.

  26. Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669–677.

    Article  PubMed  CAS  Google Scholar 

  27. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450–1456.

    Article  PubMed  CAS  Google Scholar 

  28. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. Lancet 2000, 355:253–259.

  29. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616.

    Article  PubMed  CAS  Google Scholar 

  30. Fogari R, Zoppi A, Lazzari P, et al.: ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998, 32:616–620.

    Article  PubMed  CAS  Google Scholar 

  31. Feldman RD, Schmidt ND: Quinapril treatment enhances vascular sensitivity to insulin. J Hypertens 2001, 19:113–118.

    Article  PubMed  CAS  Google Scholar 

  32. Fogari R, Zoppi A, Preti P, et al.: Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens 2001, 14:921–926.

    Article  PubMed  CAS  Google Scholar 

  33. Dominguez LJ, Barbagallo M, Jacober SJ, et al.: Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens 1997, 10:1349–1355.

    PubMed  CAS  Google Scholar 

  34. Fukuda N, Satoh C, Hu WY, et al.: Endogenous angiotensin II suppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 2001, 19:1651–1658.

    Article  PubMed  CAS  Google Scholar 

  35. Duka I, Shenouda S, Johns C, et al.: Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 2001, 38:1355–1360.

    PubMed  CAS  Google Scholar 

  36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  37. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994, 271:275–279.

    Article  PubMed  CAS  Google Scholar 

  38. Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995, 99:497–504.

    Article  PubMed  CAS  Google Scholar 

  39. Mathiesen ER, Hommel E, Hansen HP, et al.: Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999, 319:24–25.

    PubMed  CAS  Google Scholar 

  40. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group [no authors listed]. Lancet 1997, 349:1787–1792.

  41. Trevisan R, Tiengo A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive noninsulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995, 8:876–883.

    Article  PubMed  CAS  Google Scholar 

  42. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996, 156:286–289.

    Article  PubMed  CAS  Google Scholar 

  43. Ahmad J, Siddiqui MA, Ahmad H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997, 20:1576–1581.

    Article  PubMed  CAS  Google Scholar 

  44. Ravid M, Brosh D, Levi Z, et al.: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998, 128:982–988.

    PubMed  CAS  Google Scholar 

  45. Andersen S, Tarnow L, Rossing P, et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57:601–606.

    Article  PubMed  CAS  Google Scholar 

  46. Larochelle P, Flack JM, Marbury TC, et al.: Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am J Cardiol 1997, 80:1613–1615.

    Article  PubMed  CAS  Google Scholar 

  47. Weir MR, Weber MA, Neutel JM, et al.: Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens 2001, 14:567–572.

    Article  PubMed  CAS  Google Scholar 

  48. Chan JC, Critchley JA, Tomlinson B, et al.: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997, 17:72–80.

    Article  PubMed  CAS  Google Scholar 

  49. Gansevoort RT, de Zeeuw D, Shahinfar S, et al.: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens Suppl 1994, 12:S37-S42.

    PubMed  CAS  Google Scholar 

  50. Holdaas H, Hartmann A, Berg KJ, et al.: Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998, 13:3096–3102.

    Article  PubMed  CAS  Google Scholar 

  51. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582–1587.

    Article  PubMed  CAS  Google Scholar 

  52. Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675. This randomized, controlled trial demonstrated a significant improvement in the signs and symptoms of heart failure and a reduction in hospitalizations for heart failure when valsartan was added to the standard treatment regimen. Valsartan was most effective in those patients who were not receiving an ACEI because of intolerance.

    Article  PubMed  CAS  Google Scholar 

  53. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010. The LIFE study is the first large-scale randomized study to demonstrate the cardiovascular benefits of using ARBs in diabetic and nondiabetic patients with hypertension.

    Article  PubMed  CAS  Google Scholar 

  54. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003. The LIFE study is the first large-scale randomized study to demonstrate the cardiovascular benefits of using ARBs in diabetic and nondiabetic patients with hypertension.

    Article  PubMed  CAS  Google Scholar 

  55. Igarashi M, Hirata A, Yamaguchi H, et al.: Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. Hypertension 2001, 38:1255–1259.

    PubMed  CAS  Google Scholar 

  56. Murali B, Goyal RK: Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats. Pharmacol Res 2001, 44:385–389.

    Article  PubMed  CAS  Google Scholar 

  57. Higashiura K, Ura N, Miyazaki Y, Shimamoto K: Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J Hum Hypertens 1999, 13(suppl 1):S71-S74.

    Article  PubMed  CAS  Google Scholar 

  58. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878. This is a randomized, placebo-controlled study demonstrating the benefit of using an ARB in the reduction of proteinuria in type 2 diabetic patients.

    Article  PubMed  CAS  Google Scholar 

  59. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860. The first study to show the effect of any antihypertensive in reducing the incidence of doubling of the serum creatinine and the incidence of ESRD in proteinuric type 2 diabetic patients.

    Article  PubMed  CAS  Google Scholar 

  60. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869. Along with reference 59, this was the first study to show the effect of any antihypertensive in reducing the incidence of doubling of the serum creatinine and the incidence of ESRD in proteinuric type 2 diabetic patients. It also showed that losartan is superior to amlodipine in preserving renal function, despite similar reductions in blood pressure levels in the two treatment groups.

    Article  PubMed  CAS  Google Scholar 

  61. Diabetic nephropathy [no authors listed]. Diabetes Care 2002, 25:S85–S89.

  62. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905–912. This is a large-scale cohort study of nondiabetic hypertensive patients that demonstrated that up to 6 years treatment of hypertension with a thiazide diuretic, an ACEI, or a CCB did not increase the subsequent risk of development of diabetes. In contrast, treatment with a ß blocker was shown to be associated with an increase in the occurrence of new cases of diabetes.

    Article  PubMed  CAS  Google Scholar 

  63. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:713–720.

  64. Giugliano D, Acampora R, Marfella R, et al.: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997, 126:955–959.

    PubMed  CAS  Google Scholar 

  65. Jacob S, Rett K, Wicklmayr M, et al.: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996, 14:489–494.

    Article  PubMed  CAS  Google Scholar 

  66. Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886–1892.

    Article  PubMed  CAS  Google Scholar 

  67. Bakris GL: Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990, 112:707–708.

    PubMed  CAS  Google Scholar 

  68. Bakris GL, Copley JB, Vicknair N, et al.: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996, 50:1641–1650.

    Article  PubMed  CAS  Google Scholar 

  69. Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998, 54:1283–1289.

    Article  PubMed  CAS  Google Scholar 

  70. Demarie BK, Bakris GL: Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990, 113:987–988.

    PubMed  CAS  Google Scholar 

  71. Smith AC,Toto R,Bakris GL:Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998, 54:889–896.

    Article  PubMed  CAS  Google Scholar 

  72. Tatti P, Pahor M, Byington RP, et al.: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597–603.

    Article  PubMed  CAS  Google Scholar 

  73. Grimm RHJr, Flack JM, Grandits GA, et al.: Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996, 275:1549–1556.

    Article  PubMed  CAS  Google Scholar 

  74. Hirano T, Yoshino G, Kashiwazaki K, Adachi M: Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am J Hypertens 2001, 14:908–913.

    Article  PubMed  CAS  Google Scholar 

  75. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415–420.

    Article  PubMed  CAS  Google Scholar 

  76. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group [no authors listed]. JAMA 2000, 283:1967–1975.Reports the results of a part of the ALLHAT trial, which was stopped prematurely because of higher incidences of stroke, combined cardiovascular death, and doubling of the heart failure risk in the doxazosin arm compared with the chlorthalidone arm.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Endocrinology & Metabolism, University of Virginia Health System, Box 800746, 22908-0746, Charlottesville, VA, USA

    Kambiz Kalantarinia MD & Helmy M. Siragy MD

Authors
  1. Kambiz Kalantarinia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helmy M. Siragy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kalantarinia, K., Siragy, H.M. The choice of antihypertensive drugs in patients with diabetes: Angiotensin II and beyond. Curr Diab Rep 2, 423–430 (2002). https://doi.org/10.1007/s11892-002-0107-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-002-0107-1

Keywords

Search

Navigation